1. Signaling Pathways
  2. Neuronal Signaling
  3. α-synuclein
  4. α-synuclein Inhibitor

α-synuclein Inhibitor

α-synuclein Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-P99356
    Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.
  • HY-P99405
    Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.
  • HY-152552
    α-Synuclein inhibitor 8
    α-Synuclein inhibitor 8 is an active inhibitor of α-Synuclein with an IC50 value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity.
  • HY-122958
    Peucedanocoumarin III
    Peucedanocoumarin III is an inhibitor of (alpha)-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research.
  • HY-P99609
    Exidavnemab (ABBV-0805; BAN-0805) is a human IgG4 monoclonal antibody that selectively targets soluble human α-synuclein aggregates with a KD value of 18.5 pM and a KD value of 2.2 μM for α-synuclein monomers. Exidavnemab is used in Parkinson's disease research.